<DOC>
	<DOCNO>NCT02067676</DOCNO>
	<brief_summary>The purpose study assess safety increase dos potential vaccine Campylobacter without Alhydrogel® , aluminum hydroxide adjuvant . This study also assess immune response induce vaccine .</brief_summary>
	<brief_title>Safety Study Capsule-Conjugate Vaccine Prevent Campylobacter-Caused Diarrhea</brief_title>
	<detailed_description>This open-label , dose-escalating study total 48 healthy volunteer receive 2 vaccination ( one Day 0 one Day 28 ± 2 day ) . There 3 cohort ( dose level ) 2 group 8 volunteer cohort . A cohort administer one 3 intramuscular ( IM ) dose 2 μg , 5 μg , 10 μg Capsule-Conjugate Campylobacter Vaccine ( CJCV1 ) without Alhydrogel® , aluminum hydroxide adjuvant ( alum ) 125 μg . An interval le 1 week separate last dose volunteer group first dose next volunteer group ( receive different CJCV1 dos ) . Blood specimen collect interval examine systemic mucosal antigen-specific immune response . Vaccine safety actively monitor vaccination 28 day ( ± 2 day ) follow second vaccination complete study telephone follow-up approximately 6 month ( ± 1 month ) first vaccination . The total duration participation study 270 day ( include screen ) .</detailed_description>
	<mesh_term>Campylobacter Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Aluminum Hydroxide</mesh_term>
	<criteria>Healthy adult , male female , age 18 50 year ( inclusive ) time enrollment . Completion review comprehension test ( achieve 70 % accuracy ) . Signed informed consent document . Available required followup period schedule clinic visit telephone followup . Women : Negative pregnancy test understanding ( informed consent ) become pregnant study within three month last vaccine dose ( Day 28 ) . Sexually active female , unless surgically sterile least one year postmenopausal , must use effective method avoid pregnancy ( include oral implanted contraceptive , intrauterine device ( IUD ) , female condom , diaphragm spermicide , cervical cap , abstinence , use condom sexual partner , sterile sexual partner ) prior dose study vaccine . Female subject unable bear child must note primary care provider obstetrics gynaecology ( OB/GYN ) proof documentation ( eg , tubal ligation hysterectomy ) . If volunteer becomes pregnant study , PI notify study monitor , sponsor , local institutional review board ( IRB ) . The volunteer ask provide serial followup , include copy clinic visit status pregnancy well health information infant follow delivery . Health 1 . Health problem affect study participation medical history ( specifically include chronic medical condition diabetes mellitus hypertension condition require daily therapy would place volunteer increase risk adverse event ( AEs ) . Study clinician , consultation PI , use clinical judgment casebycase basis ass safety risk criterion . The PI consult research monitor appropriate . 2 . Clinically significant abnormality physical examination 3 . Use immunosuppressive drug , corticosteroid chemotherapy , course study immunosuppressive illness , include IgA deficiency ( define serum IgA level detection ) 4 . Women pregnant plan become pregnant study period plus 3 month beyond last vaccine dose currently nurse woman 5 . Participation research involve another investigational product 30 day plan date first vaccination last study safety visit . 6 . Positive blood test HIV1 ( human immunodeficiency virus cause AIDS ) 7 . Positive blood test hepatitis B surface antigen ( HBsAG ; virus cause hepatitis B ) 8 . Positive blood test antiHCV antibody ( virus cause hepatitis C ) 9 . Clinically significant abnormality basic laboratory screen 10 . Presence significant unexplained laboratory abnormality opinion PI may potentially confound analysis study result Research Specific 11 . Regular use ( weekly often ) antidiarrheal , anticonstipation , antacid therapy 12 . Abnormal bowel habit define few 3 stool per week 3 loose/liquid stool per day 13 . Personal family history inflammatory arthritis 14 . Personal history irritable bowel syndrome 15 . Positive blood test HLAB27 16 . History allergy vaccine 17 . History allergy alum 18 . History GuillainBarré Syndrome neuroimmunological disorder Prior Exposure Campylobacter 19 . History traveler ' diarrhea residence ( &gt; 2 month ) past 3 year country potentially high Campylobacter rate include Africa , South America , Central America , Asia ( except Japan ) . 20 . Occupation involve handle Campylobacter bacteria vaccine product currently past 3 year . 21 . History microbiologically confirm Campylobacter infection . 22 . Received previous experimental Campylobacter vaccine live Campylobacter challenge .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Campylobacter jejuni</keyword>
</DOC>